Stay updated on Open-Label Surufatinib in EU NET Patients Clinical Trial
Sign up to get notified when there's something new on the Open-Label Surufatinib in EU NET Patients Clinical Trial page.

Latest updates to the Open-Label Surufatinib in EU NET Patients Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3. No study data or content were changed.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updates: added v3.4.2 and removed v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page shows a minor revision update from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision entry updated from v3.3.3 to v3.3.4; core study details remain unchanged.SummaryDifference0.0%

- Check83 days agoChange Detected- A consolidated Locations section was added listing study sites across Alabama, California, Georgia, New York, and Texas, with the previous state-specific location headings removed. The page revision was updated to v3.3.3.SummaryDifference0.6%

- Check112 days agoChange DetectedThe page revision tag was updated from v3.2.0 to v3.3.2.SummaryDifference0.0%

Stay in the know with updates to Open-Label Surufatinib in EU NET Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Open-Label Surufatinib in EU NET Patients Clinical Trial page.